论文部分内容阅读
目的探讨紫杉醇联合卡培他滨一线治疗晚期胃癌的应用价值。方法选择2011年1月—2013年1月收治的70例经病理检查证实的晚期胃癌患者,随机分成两组,对照组35例予紫杉醇+顺铂+氟尿嘧啶治疗,观察组35例予紫杉醇+卡培他滨治疗,对比两组近期疗效及不良反应。结果两组有效率比较无显著差异(P>0.05)。观察组患者不良反应中恶心、呕吐(57.14%)、骨髓抑制(51.43%)、手足综合症(14.29%)、口腔黏膜炎(22.86%)发生率与对照组比较明显降低,组间差异显著(P<0.05)。结论紫杉醇联合卡培他滨一线治疗晚期胃癌疗效显著、安全性高,可作为临床推广应用方案。
Objective To investigate the value of paclitaxel combined with capecitabine in the treatment of advanced gastric cancer. Methods Seventy patients with advanced gastric cancer confirmed by pathology from January 2011 to January 2013 were randomly divided into two groups. The control group was treated with paclitaxel plus cisplatin plus fluorouracil, and the observation group with paclitaxel plus card Perturabine treatment, the two groups compared the short-term efficacy and adverse reactions. Results There was no significant difference between the two groups (P> 0.05). The incidence of nausea and vomiting (57.14%), myelosuppression (51.43%), hand-foot syndrome (14.29%) and oral mucositis (22.86%) in observation group were significantly lower than those in control group P <0.05). Conclusion Paclitaxel combined with capecitabine first-line treatment of advanced gastric cancer with significant efficacy, high safety, can be used as a clinical application program.